OOIR: Observatory of International Research

Papers

(The H4-Index of Thrombosis Research is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Is all collagen the same for platelet testing? Editorial on “Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen subs	52
PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of superior vena cava syndrome in lung cancer patients	51
DOACs: A perfect fit for patients with bariatric surgery?	48
Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms	47
Linezolid impair proplatelet formation by reducing mitochondrial energy metabolism in MEG-01 cells	46
Major in-hospital bleeding in patients with pulmonary embolism treated with systemic thrombolysis	42
Distinct Immunologic Mediators Are Associated with Venous Thromboembolism in Multiply Injured Patients	37
A novel role of acellular hemoglobin in hemolytic thrombosis	36
PO-08: Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms	36
PO-51: Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery	35
Investigation of the impact of antithrombin deficiency on the inflammatory response: Results from a single centre cohort study	35
Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination	35
Unveiling the predictive capacity of inflammatory and platelet markers for central retinal artery occlusion	34
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients	34
Corrigendum to “Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation” [Thromb. Res. 229 (2023) 53–68]	33
Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors	33
Editorial Board	33
Regulation of fibrinogen synthesis	31
Crosstalk between hemostasis and immunity in cancer pathogenesis	31
The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis	30
Predicting post-discharge venous thromboembolism and bleeding among medical patients: External validation of a novel risk score utilizing ubiquitous biomarkers	29
Assessing the risk of venous thromboembolism in trans masculine persons on gender-affirming hormone therapy: A literature review	28
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice	28
Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study	28
Thrombosis after surgical splenectomy – why, in whom and can we prevent it?	28

Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban	27
The maternal hemostatic shift: Understanding VTE risk in pregnancy and postpartum	26
Impact of aetiology and liver stiffness on thrombin generation in compensated cirrhosis	26